Moiz Diwan

Moiz Diwan is a director within the Process Research and Development organization at AbbVie. Moiz has led early to late-stage pharmaceutical development teams involving drug substance control strategy development, establishing global supply chain, process tech-transfer and scale-up, and authored global regulatory filings for 1st Gen. HCV Viekira and HCV Next Gen. Mavyret drugs. Presently, Moiz is leading Center of Excellence for Enabling Technology Development, a cross functional team of chemists, engineers and PAT scientists impacting all small molecule projects. The center focus on fundamentals?driven process development through application of enabling technologies, data rich experimentation, and predictive modeling. This center has supported commercial process development and regulatory submissions for 6 approved drugs in last 4 years. Moiz also built from ground-up FAST – Flow and Automation Strategy Team at AbbVie. FAST is a multi-disciplinary team of scientists and engineers across Discovery, Development, and Operations Manufacturing organization to efficiently share capabilities and resources, facilitate collaboration and provide strategic advancement on lab automation, plant automation, information management and continuous manufacturing technologies to maximize the impact. Moiz has captured his scientific contribution in over 50 journal publications, patents, book chapters, invited seminars and conference presentations. At AbbVie, Moiz is recipient of President Award and multiple Excellence Awards for global regulatory submissions and Launch of HCV NXT Gen. Mavyret, and AbbVie Volwiler Scientific Society Outstanding Team Award for process development and filing of the HCV Viekira Pak. Moiz completed his M.S. and PhD degree from Purdue University in Chemical engineering and bachelor’s degree from Indian Institute of Technology in Chemical Engineering.